Table 3 PFS comparisons across patients
From: Factors affecting survival and prognosis in extensive stage small cell lung cancer
PFS (months) | 2 years % | 5 years % | Median (% 95 CI) | p |
|---|---|---|---|---|
First-line | 4.5 | 4.1 | 7.0 (6.23–7.76) | |
Age | ||||
< 65 | 4.0 | 3.4 | 8.0 (6.94–9.05) | 0.488 |
≥ 65 | 5.6 | 5.6 | 7.0 (5.77–8.22) | |
Gender | ||||
Female | 4.0 | - | 8.0 (6.65–9.44) | 0.710 |
Male | 4.7 | 4.1 | 7.0 (6.13–7.86) | |
Tumor localization | ||||
Right | 3.6 | 3.6 | 8.0 (7.07–8.92) | 0.434 |
Left | 5.5 | 4.6 | 7.0 (6.04–7.95) | |
Brain metastasis | ||||
No | 5.7 | 5.2 | 7.0 (6.05–7.94) | 0.005 |
Yes | - | - | 7.0 (5.95–8.04) | |
Pleura metastasis | ||||
No | 3.8 | 3.8 | 7.0 (6.19–7.80) | 0.402 |
Yes | 7.0 | 5.3 | 8.0 (5.80–10.19) | |
Liver metastasis | ||||
No | 6.0 | 5.3 | 8.0 (7.05–8.94) | < 0.001 |
Yes | 1.2 | 1.2 | 5.0 (3.93–6.06) | |
Surrenal metastasis | ||||
No | 5.1 | 4.5 | 7.0 (6.06–7.94) | 0.417 |
Yes | 2.8 | 2.8 | 7.0 (5.66–8.33) | |
Bone metastasis | ||||
No | 5.6 | 4.5 | 8.0 (6.81–9.18) | 0.027 |
Yes | 3.4 | 3.4 | 7.0 (6.20–7.79) | |
Pancreas metastasis | ||||
No | 4.6 | 4.1 | 7.0 (6.22–7.77) | 0.229 |
Yes | - | - | 5.0 (0.19–9.80) | |
1. Line treatment | ||||
Cisplatin+etoposide | 3.9 | 3.3 | 7.0 (6.13–7.86) | < 0.001 |
Carboplatin+etoposide | - | - | 5.0 (3.31–6.88) | |
Oral etoposide | - | - | 2.0 (0.00–4.06) | |
Carboplatin+etoposide+atezolizumab | 26.7 | - | 20.0 (17.21–22.78) | |
2. Line treatment | ||||
Topotecan | - | - | 8.0 (7.02–8.97) | < 0.001 |
Cisplatin+irinotecan | - | - | 8.0 (6.48–9.51) | |
Cisplatin+etoposide | 7.1 | - | 14.0 (12.16–15.83) | |
CAV | - | - | 5.0 (3.45–6.55) | |
Other | 0.0 | - | 9.0 (8.14–9.85) | |